Hunter Taubman Fischer & Li LLC acted as US counsel to Bison while Sidley Austin LLP is acted as legal counsel to Xynomic. Ogier has acted as British Virgin Islands counsel on NASDAQ listed Bison Capital Acquisition Corp.
Bison Capital Acquisition Corp. (“BCAC”, NASDAQ: BCAC) and Xynomic Pharmaceuticals, Inc. (“Xynomic”), a U.S.-China clinical stage innovative oncology drug development company, have signed a definitive merger agreement. Upon completion of the merger, Xynomic will become a wholly-owned subsidiary and the operating business of BCAC, and BCAC will change its name to “Xynomic Pharmaceuticals Holdings, Inc.”
Xynomic, founded in 2016 by industry veterans and headquartered in the U.S. with operations in Raleigh, North Carolina and Shanghai, China, is principally engaged in the research, development and commercialization of innovative targeted cancer therapeutics in the U.S., Europe and China. Xynomic has in-licensed a clinical stage drug candidate from Pharmacyclics/AbbVie and a pre-clinical stage drug candidate from Boehringer Ingelheim and is collaborating with Janssen R&D, LLC in a clinical trial of a combination therapy. Xynomic focuses on orally delivered small molecule drugs. Xynomic builds and develops its oncology pipeline through both in-licensing from strategic partners and internal research and development efforts supported by its scientists with expertise in tyrosine kinase inhibition and epigenetic modification. The current investors of Xynomic include, among others, Northern Light Venture Capital, Prosperico Ventures and Hakim Unique.
Hunter Taubman Fischer & Li advised Bison with a team led by Arila Zhou (Picture).
Ogier acted as British Virgin Islands counsel of Bison Capital Acquisition Corp. with Michael Killourhy and associate David Mathews.
Sidley Austin advised Xynomic with a team led by Wenseng “Wendy” Pan.